Logo image of LMDX

LUMIRADX LTD (LMDX) Stock Fundamental Analysis

NASDAQ:LMDX - KYG5709L1095 - Common Stock

0.016 USD
-0.02 (-53.49%)
Last: 1/8/2024, 8:17:43 PM
0.0136 USD
0 (-15%)
After Hours: 1/8/2024, 8:17:43 PM
Fundamental Rating

1

Taking everything into account, LMDX scores 1 out of 10 in our fundamental rating. LMDX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. LMDX may be in some trouble as it scores bad on both profitability and health. LMDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LMDX had negative earnings in the past year.
In the past year LMDX has reported a negative cash flow from operations.
In the past 5 years LMDX always reported negative net income.
LMDX had a negative operating cash flow in each of the past 5 years.
LMDX Yearly Net Income VS EBIT VS OCF VS FCFLMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -100M -200M -300M -400M

1.2 Ratios

LMDX has a Return On Assets of -99.18%. This is amonst the worse of the industry: LMDX underperforms 82.91% of its industry peers.
Industry RankSector Rank
ROA -99.18%
ROE N/A
ROIC N/A
ROA(3y)-54.66%
ROA(5y)-52.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMDX Yearly ROA, ROE, ROICLMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 100 -100 200 300 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LMDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMDX Yearly Profit, Operating, Gross MarginsLMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 -200 -400

More info and screens

1

2. Health

2.1 Basic Checks

LMDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LMDX has less shares outstanding
LMDX has a worse debt/assets ratio than last year.
LMDX Yearly Shares OutstandingLMDX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M
LMDX Yearly Total Debt VS Total AssetsLMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -6.66, we must say that LMDX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.66, LMDX is doing worse than 72.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.66
ROIC/WACCN/A
WACC4.03%
LMDX Yearly LT Debt VS Equity VS FCFLMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 200M -200M 400M

2.3 Liquidity

LMDX has a Current Ratio of 1.97. This is a normal value and indicates that LMDX is financially healthy and should not expect problems in meeting its short term obligations.
LMDX's Current ratio of 1.97 is on the low side compared to the rest of the industry. LMDX is outperformed by 74.37% of its industry peers.
LMDX has a Quick Ratio of 1.01. This is a normal value and indicates that LMDX is financially healthy and should not expect problems in meeting its short term obligations.
LMDX has a worse Quick ratio (1.01) than 82.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.01
LMDX Yearly Current Assets VS Current LiabilitesLMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.80% over the past year.
Looking at the last year, LMDX shows a very negative growth in Revenue. The Revenue has decreased by -68.26% in the last year.
LMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 122.52% yearly.
EPS 1Y (TTM)1.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.41%
Revenue 1Y (TTM)-68.26%
Revenue growth 3Y122.52%
Revenue growth 5YN/A
Sales Q2Q%-53.02%

3.2 Future

Based on estimates for the next years, LMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.53% on average per year.
LMDX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -3.56% yearly.
EPS Next Y70.33%
EPS Next 2Y33.38%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue Next Year-64.72%
Revenue Next 2Y-27.23%
Revenue Next 3Y-9.52%
Revenue Next 5Y-3.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LMDX Yearly Revenue VS EstimatesLMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M
LMDX Yearly EPS VS EstimatesLMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LMDX. In the last year negative earnings were reported.
Also next year LMDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LMDX Price Earnings VS Forward Price EarningsLMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMDX Per share dataLMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as LMDX's earnings are expected to grow with 22.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.38%
EPS Next 3Y22.53%

More info and screens

0

5. Dividend

5.1 Amount

LMDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUMIRADX LTD

NASDAQ:LMDX (1/8/2024, 8:17:43 PM)

After market: 0.0136 0 (-15%)

0.016

-0.02 (-53.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10 2023-11-10/amc
Earnings (Next)03-19 2024-03-19/amc
Inst Owners0.11%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.63M
Analysts82.5
Price Target1.22 (7525%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.35%
Min EPS beat(2)-12.04%
Max EPS beat(2)5.34%
EPS beat(4)1
Avg EPS beat(4)-35.59%
Min EPS beat(4)-77.22%
Max EPS beat(4)5.34%
EPS beat(8)2
Avg EPS beat(8)-68.43%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.56%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)11.29%
Revenue beat(4)2
Avg Revenue beat(4)3.57%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)11.29%
Revenue beat(8)5
Avg Revenue beat(8)10.8%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.42%
EPS NY rev (1m)0%
EPS NY rev (3m)5.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0.77
BVpS-1.31
TBVpS-1.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.66%
ROA(5y)-52.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.03%
Cap/Sales 8.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.01
Altman-Z -6.66
F-Score1
WACC4.03%
ROIC/WACCN/A
Cap/Depr(3y)359.47%
Cap/Depr(5y)273.18%
Cap/Sales(3y)27.1%
Cap/Sales(5y)32.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.41%
EPS Next Y70.33%
EPS Next 2Y33.38%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-68.26%
Revenue growth 3Y122.52%
Revenue growth 5YN/A
Sales Q2Q%-53.02%
Revenue Next Year-64.72%
Revenue Next 2Y-27.23%
Revenue Next 3Y-9.52%
Revenue Next 5Y-3.56%
EBIT growth 1Y-149.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.43%
EBIT Next 3Y23.29%
EBIT Next 5YN/A
FCF growth 1Y22.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.46%
OCF growth 3YN/A
OCF growth 5YN/A